GENERAL29 Sept 2026
Gujarat Themis secures $58 million private credit for Japanese acquisition
Gujarat Themis, an Indian drugmaker founded in 1981, has raised $58 million from Orion Capital Asia. The money will help fund its ¥21.5-billion takeover of Japan's MicroBiopharm. The company was India's first to make the anti-tuberculosis drug Rifampicin commercially. For business owners, it's a reminder that private credit is funding overseas buys. If you plan cross-border deals, check funding costs and tax treatment early.
Key Statutory Highlights
- Gujarat Themis secured $58 million from Orion Capital Asia to part-fund its acquisition of Japan's MicroBiopharm.
- The deal is valued at ¥21.5 billion, and the money comes through private credit rather than a bank loan.
- Gujarat Themis, founded in 1981, was India's first company to commercially produce the anti-tuberculosis drug Rifampicin.
Actionable Advice for Taxpayers / Founders:If your business is planning an overseas acquisition or bringing in private credit, talk to your CA early about the funding cost and the tax and reporting treatment before you commit.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: